HACKENSACK, N.J., April 12, 2016 /PRNewswire/ -- Champions
Oncology, Inc. (NASDAQ:CSBR) is pleased to announce the appointment
of Dr. Philip Breitfeld to its Board
of Directors. Dr. Breitfeld has more than 30 years of
experience in oncology. His appointment will further the
company's efforts to accelerate growth and increase the adoption of
its technology platform.
Dr. David Sidransky, founder and
Chairman of the Board of Directors commented, "We are very excited
to have an oncologist of Phil's caliber and experience join our
Board of Directors. Phil has a distinguished career in
academia and industry. He has leveraged the depth and breadth
of this knowledge of oncology to become a thought leader in the
strategy of oncology drug development. His insights into the
strategic issues facing the pharmaceutical industry and the
opportunities for Champions to capitalize on its technology
platform will be invaluable to our board conversations."
Philip Breitfeld, MD was most
recently Global Vice President at Quintiles, responsible for the
Therapeutic Centers of Excellence. Prior to that, he led the
Oncology Center of Excellence at Quintiles where he worked with
many large, mid-size and emerging biopharmaceutical firms. He
held senior clinical development positions at Merck KGaA (EMD
Serono in the US), where he led oncology development in the US, and
at BioCryst, where he led oncology development and was Associate
Chief Medical Officer. Prior to his career in industry, he
held academic positions at Harvard, University
of Massachusetts, Indiana
University, and Duke. He has approximately 50
publications in the literature dealing with basic cell and
molecular biology, and translational and clinical oncology.
He was trained in Pediatric Hematology/Oncology at the Dana-Farber
Cancer Institute, was a visiting scientist at the Whitehead
Institute at MIT, received his medical
degree (MD) from the University of
Rochester, and his undergraduate degree (AB in chemistry)
from Princeton.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The company's
technology platform is a novel approach to personalizing cancer
care based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting
engraftments, or Champions TumorGrafts, in a manner that preserves
the biological characteristics of the original human tumor in order
to determine the efficacy of a treatment regimen. The Company
uses this technology in conjunction with related services to offer
solutions for two customer groups: Personalized Oncology
Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions,
in which pharmaceutical and biotechnology companies seeking
personalized approaches to drug development can lower the cost and
increase the speed of developing new drugs. TumorGrafts are
procured through agreements with a number of institutions in the
U.S. and overseas as well as through Champions' Personalized
Oncology Solutions business.
For more information, visit www.championsoncology.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-announces-addition-to-board-of-directors-300250093.html
SOURCE Champions Oncology, Inc.